Key clinical point: Ruxolitinib plus decitabine has demonstrated activity in patients with accelerated phase or blast phase myeloproliferative neoplasms (MPNs), but the combination will not proceed to a phase 3 trial.

Major finding: Of 18 evaluable patients, nine achieved a partial response, and two achieved a complete response with incomplete count recovery.

Study details: A phase 2 trial of 25 patients with accelerated phase or blast phase MPNs.

Disclosures: The trial was supported by the National Institutes of Health, National Cancer Institute, and Incyte Corporation. Dr. Rampal reported having no conflicts of interest.